IN 2016, AN ESTIMATED 564,000 CANADIANS SUFFERED FROM DEMENTIA. By 2031, says the Alzheimer’s Society of Canada, that figure will rise to 937,000. In the US it is estimated that the Alzheimer’s burden will triple from 5.3 million people today …
Latest News From Lumira Ventures
Endotronix Joins American Heart Association’s Center for Health Technology & Innovation to Broaden the Use of Guideline-Based Care for Heart Failure Patients
LISLE, Ill., June 28, 2018 /PRNewswire/ — Endotronix, Inc., a digital health, medtech company dedicated to advancing the treatment of heart failure, today announced they have joined the American Heart Association’s Center for Health Technology & Innovation’s (CHTI) Innovators Network. The collaboration allows Endotronix …
Aurinia Initiates Clinical Trials Broadening the Development of Voclosporin
VICTORIA, British Columbia–(BUSINESS WIRE)–Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced the enrollment of the first patients into the AURORA 2 extension study in lupus nephritis and the initiation of its …
Zymeworks Closes Previously Announced Public Offering
VANCOUVER, British Columbia–(BUSINESS WIRE)–Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, announced today that it has closed its previously announced underwritten public offering (the “Offering”) of 6,210,000 common shares, including …
G1 Therapeutics Announces Appointment of New Members to the Board of Directors
RESEARCH TRIANGLE PARK, N.C., June 08, 2018 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that Cynthia Schwalm and Willie Deese have been appointed to its board of directors, effective June 7, 2018. “We are pleased to welcome Cynthia and Willie as new independent …
Celtaxsys Announces Last Patient, Last Visit in Landmark CF Phase 2b Lung Function Preservation Trial, Clinical Results Expected in July
Phase 2b Trial Design and Enrolled Patient Demographics to be Presented at the 41st European Cystic Fibrosis Society Conference ATLANTA – May 17, 2018 – Celtaxsys, Inc., a clinical stage pharmaceutical development company focused on advancing treatments for patients with …
Three Finalists Announced for the 2018 Bloom Burton Award
TORONTO–(BUSINESS WIRE)–Bloom Burton & Co. (“Bloom Burton”) is pleased to announce the three finalists for the 2018 Bloom Burton Award. The finalists are: Clarissa Desjardins, Founder and CEO, Clementia Pharmaceuticals Inc.; Richard Glickman, Founder, CEO and Chairman of the Board, …
Zymeworks and Daiichi Sankyo Expand Immuno-Oncology Collaboration Focused on Bispecific Antibodies
Vancouver, Canada, Tokyo, Japan and Basking Ridge, NJ (May 14, 2018)– Zymeworks Inc. (NYSE/TSX: ZYME), aclinical-stage biopharmaceutical company developing multifunctional therapeutics, and Daiichi Sankyo Company, Limited (Daiichi Sankyo) announced today that they entered into a new license agreement, building upon …
Engage Therapeutics Doses First Patient in Phase 2b Trial of Epilepsy Seizure Rescue Therapy Staccato® Alprazolam
Topline Data Expected H2-2019 Peachtree BioResearch Solutions to Execute Multi-Center Trial SUMMIT, N.J., May 03, 2018 (GLOBE NEWSWIRE) — Engage Therapeutics, Inc., today announced dosing of the first patient in its multi-center, double-blind, randomized Phase 2b StATES (Seizures) trial to …
Cardiac Dimensions Announces $39 Million Series B Financing for Innovative Device to Treat Patients With Heart Failure
KIRKLAND, Wash.–(BUSINESS WIRE)–Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatments for patients with heart failure, today announced the company has closed a $39 million Series B financing. The round includes new investor, Australia-based Hostplus, venture debt …
Opsens Applauds Japanese Government New Regulation Supporting Diagnosis, Such as FFR, Before Treatment of Coronary Stenosis
Quebec City, Quebec, April 24, 2018 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS)(OTCQX:OPSSF) applauds Japan’s Ministry of Health, Labor and Welfare (“MHLW”) on its new regulation requiring the evaluation of any coronary stenosis prior to its treatment, specifically mentioning Fractional Flow Reserve (“FFR”) as …
Zymeworks and Celgene Expand Bispecific Antibody Collaboration
VANCOUVER, British Columbia–(BUSINESS WIRE)–Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that Celgene Corporation has exercised its right to expand its collaboration agreement for the research, development, and commercialization of bispecific antibody therapeutics using Zymeworks’ …
Endotronix Hires Seasoned Life Sciences Executive John Flavin as CFO
LISLE, IL – APRIL 12, 2017- Endotronix, Inc., a medical technology company providing device and digital health solutions for heart failure management, today announced the appointment of seasoned life sciences executive and entrepreneur John Flavin as Chief Financial Officer. He …
Orthofix Announces Agreement to Acquire Spinal Kinetics
Transaction to expand Orthofix’s Spine Fixation portfolio with innovative artificial disc designed to restore natural and physiologic motion to the spine. LEWISVILLE, Texas–(BUSINESS WIRE)–Orthofix International N.V. (NASDAQ:OFIX), a global medical device company focused on musculoskeletal healing products and value-added services, …
G1 Therapeutics Announces Closing of Offering of Common Stock
RESEARCH TRIANGLE PARK, N.C., March 12, 2018 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced the closing of an underwritten public offering of 3,910,000 shares of its common stock at a public offering price of $29.50, including 510,000 shares sold …